Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Sorry, this entry is only available in 中文.類型: 連結 作者: Feng-Cai Zhu et al. 出處: The Lancet 連結:...